Search
News
Important Only
Moleculin Biotech Inc - To Unblind Miracle Trial Data Before June 30, 2026 - SEC Filing
May 13 (Reuters) - Moleculin Biotech Inc MBRX.O:MOLECULIN BIOTECH INC - TO UNBLIND MIRACLE TRIAL DATA BEFORE JUNE 30, 2026 - SEC FILINGMOLECULIN BIOTECH INC - MIRACLE TRIAL ON TRACK TO COMPLETE PART A RECRUITMENT IN Q3 2026 - SEC FILINGReuters
2 hours ago
Ironwood Pharmaceuticals Inc - Gregory Martini Resigns As CFO Effective May 15, 2026 - SEC Filing
May 13 (Reuters) - Ironwood Pharmaceuticals Inc IRWD.O:IRONWOOD PHARMACEUTICALS INC - GREGORY MARTINI RESIGNS AS CFO EFFECTIVE MAY 15, 2026 - SEC FILINGIRONWOOD PHARMACEUTICALS INC - APPOINTS RONALD SILVER AS INTERIM CFO EFFECTIVE MAY 15, 2026 - SEC FILINGReuters
2 hours ago
High-Trend International Group Announces Pricing Of $15 Million Registered Direct Offering With Global Institutional Investors
May 13 (Reuters) - High-Trend International Group HTCO.O:HIGH-TREND INTERNATIONAL GROUP ANNOUNCES PRICING OF $15 MILLION REGISTERED DIRECT OFFERING WITH GLOBAL INSTITUTIONAL INVESTORSHIGH-TREND INTERNATIONAL GROUP - TO SELL 2,307,700 CLASS A ORDINARY SHARES AT $6.50 EACHReuters
2 hours ago
Century Therapeutics posts smaller-than-expected Q1 net loss on lower R&D spend
OverviewUS biotech firm's Q1 net loss narrowed, beating analyst expectationsQ1 operating loss also beat analyst expectationsCompany ended Q1 with $217 mln in cash, projects runway into Q1 2029OutlookCentury projects cash runway into 1Q 2029Result DriversLOWER R&D SPENDING - Co said Q1 R&...Reuters
2 hours ago
Urogen Pharma Ltd - Reports 36-Month Duration Of Response Of 64.5% For ZUSDURI In Phase 3 Envision Trial
May 13 (Reuters) - Urogen Pharma Ltd UR8.F:UROGEN PHARMA LTD - REPORTS 36-MONTH DURATION OF RESPONSE OF 64.5% FOR ZUSDURI IN PHASE 3 ENVISION TRIALUROGEN PHARMA LTD - MEDIAN DURATION OF RESPONSE NOT REACHED AT 35.5 MONTHS FOLLOW-UPUROGEN PHARMA LTD - SERIOUS ADVERSE REACTIONS OCCURRED IN 12% OF PATI...Reuters
3 hours ago
Spruce Biosciences Q1 net loss narrows on lower expenses
OverviewU.S. biopharma firm's Q1 net loss narrowed on lower operating expensesCompany closed $69 mln public offering in April, extending cash runway into H2 2027Preliminary cash and equivalents were $107.3 mln as of April 30, 2026OutlookSpruce expects to submit BLA for TA-ERT in Q4 2026Spruce ex...Reuters
3 hours ago
Diginex Appoints Archana Kotecha As Chief Impact Officer To Advance Human Rights And Scale Supply Chain Solutions In A $9.6B Market
May 13 (Reuters) - Diginex Ltd DGNX.O:DIGINEX APPOINTS ARCHANA KOTECHA AS CHIEF IMPACT OFFICER TO ADVANCE HUMAN RIGHTS AND SCALE SUPPLY CHAIN SOLUTIONS IN A $9.6B MARKETReuters
3 hours ago
Tyra Biosciences' Q1 net loss widens on higher R&D costs
OverviewU.S. biotech firm's Q1 net loss widened yr/yr as R&D expenses increasedCompany ended Q1 with $383.5 mln in cash and marketable securities, runway into 2H 2028OutlookCompany says current cash position expected to fund operations into 2H 2028Result DriversR&D SPENDING - Co said hig...Reuters
3 hours ago
Miner Orvana's Q2 revenue rises 70% quarter-over-quarter on higher prices and volumes
OverviewCanada gold-copper-silver miner's fiscal Q2 revenue rose 70% quarter-over-quarter to $54.4 mlnCompany returned to profitability with Q2 net income of $19.6 mln after prior quarter lossOxide stockpile processing at Bolivia's Don Mario expected to commence in coming weeksOutlookOrvana ...Reuters
3 hours ago
Protara Therapeutics Q1 net loss widens on higher expenses
OverviewUS biotechnology firm's Q1 net loss widened yr/yr on higher R&D and administrative expensesCompany ended Q1 with $177 mln in cash, expected to fund operations into 2028Protara plans BLA submission for TARA-002 in lymphatic malformations in 2H 2027OutlookProtara intends to submit a BL...Reuters
3 hours ago
Lantern Pharma Inc. Announces Up To $9.25 Million Registered Direct Offering With Existing Holders And A Single Institutional Investor
May 13 (Reuters) - Lantern Pharma Inc LTRN.O:LANTERN PHARMA INC. ANNOUNCES UP TO $9.25 MILLION REGISTERED DIRECT OFFERING WITH EXISTING HOLDERS AND A SINGLE INSTITUTIONAL INVESTORReuters
3 hours ago
Assertio To Be Acquired By Zydus Worldwide DMCC For $23.50 Per Share In Cash
May 13 (Reuters) - Assertio Holdings Inc ASRT.O:ASSERTIO TO BE ACQUIRED BY ZYDUS WORLDWIDE DMCC FOR $23.50 PER SHARE IN CASHASSERTIO HOLDINGS INC - ALL-CASH TENDER OFFER VALUED AT $166.4 MILLIONASSERTIO HOLDINGS INC - TO BE BOUGHT BY ZYDUS WORLDWIDE DMCC FOR $23.50 PER SHARE IN CASHASSERTIO HOLDINGS...Reuters
3 hours ago
Featured Tools
Top News
Cerebras Systems IPO 2026: Date, Price, Valuation, and Whether CBRS Is Worth Buying
April 2026 CPI Preview: Will Hot Inflation Crush Nasdaq, S&P 500 & NVDA? Explosive Market Reaction Guide
Copper Prices Near All-Time Highs. Citi: If Strait of Hormuz Is Unblocked, Price Will Rise to $15,000 by Year-End
SK Hynix Surges 15% to New High: HBM Shortage Until 2028, How Much Longer Can AI Memory King Rise?
PPI Report April 2026: How Inflation Data Is Moving HIMS, CEG, and PLUG Stock Today
Market Movers
Tradingkey
